ScholarIQanswers from OpenAlex
Bayer (Germany)
InstitutionResearch output, impact & collaborations
Bayer (Germany) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Bayer (Germany)?
ScholarIQrecord summary
Bayer (Germany) is a research organisation in Leverkusen, DE. OpenAlex records 32,155 works and 1,978,111 citations for it. 7,550 researchers list it as their most recent affiliation.
How many works does Bayer (Germany) have?
ScholarIQindexed works
Bayer (Germany) has 32,155 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Bayer (Germany) have?
ScholarIQcitation count
Bayer (Germany) has 1,978,111 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Bayer (Germany)?
ScholarIQresearcher count
Bayer (Germany) has 7,550 researchers in the ScholarIQ index.
What is the average h-index at Bayer (Germany)?
ScholarIQavg h-index
Bayer (Germany) has an average h-index of 38 in OpenAlex.
What is the ROR of Bayer (Germany)?
ScholarIQror
The ROR for Bayer (Germany) is on the source record.
What is the OpenAlex record for Bayer (Germany)?
ScholarIQopenalex
The OpenAlex for Bayer (Germany) is on the source record.
Who are the most-cited researchers behind Bayer (Germany)?
ScholarIQtop researchers by citations
What are the most-cited papers on Bayer (Germany)?
ScholarIQmost cited works
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
Christoph Male, Anthonie W.A. Lensing, Joseph S. Palumbo, Riten Kumar, Ildar Nurmeev, Kerry Hege, Damien Bonnet, Philip Connor, Hélène L. Hooimeijer, Marcela Torres, Anthony K.C. Chan, Gili Kenet, Susanne Holzhauer, Amparo Santamaría, Pascal Amédro, Elizabeth Chalmers, Paolo Simioni, Rukhmi Bhat, Donald L. Yee, O. Lvova, Jan Beyer‐Westendorf, Tina Biss, Ida Martinelli, Paola Saracco, Marjolein Peters, Krisztián Kállay, Cynthia Gauger, M. Patricia Massicotte, Guy Young, Ákos F. Pap, Madhurima Majumder, William T. Smith, Jürgen F. Heubach, Scott D. Berkowitz, Kirstin Thelen, Dagmar Kubitza, Mark Crowther, Martin H. Prins, Paul Monagle, Angelo Claudio Molinari, Ulrike Nowak- Gottl, Juan José Chain, Jeremy Robertson, Katharina Thom, Werner Streif, Rudolf Schwarz, Klaus Schmitt, Gernot Grangl, An Van Damme, Philip Maes, Veerle Labarque, Antônio Sérgio Petrilli, Sandra Loggeto, Estela Azeka, Leonardo R. Brandão, Doan Le, Christine Sabapathy, Paola Giordano, Runhui Wu, Jie Ding, Wenyan Huang, Jianhua Mao, Päivi M. Lähteenmäki, Pascal Amédro, Stéphane Decramer, Toralf Bernig, Martin Chada, Gcf Chan, Krisztian Kally, Beatrice Nolan, Shoshana Revel‐Vilk, Hannah Tamary, Carina Levin, Daniela Tormene, Maria Abbattista, Andrea Artoni, Takanari Ikeyama, Ryo Inuzuka, Satoshi Yasukochi, Michelle Morales Soto, Karina Anastacia Solís‐Labastida, Monique H. Suijker, Marike Bartels, R. Y. J. Tamminga, C Heleen Van Ommen, D. Maroeska W. M. te Loo, Rui Anjos, Lyudmila Zubarovskaya, Natalia Popova, Elena Samochatova, М. Б. Белогурова, Pavel Svirin, Tatiana Shutova, В. В. Лебедев, О. Л. Барбараш, Pei Lin Koh, J. Mei, Ľudmila Podracká, Rubén Berrueco, María Florencia Fernández
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
Luís M. Ruilope, Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Pantelis Sarafidis, Roland E. Schmieder, Amer Joseph, Nicole Rethemeier, Christina Nowack, George L. Bakris, on behalf of the FIDELIO-DKD Investigators
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
Hiddo J.L. Heerspink, Rajiv Agarwal, George L. Bakris, David Z.I. Cherney, Carolyn S.P. Lam, Brendon L. Neuen, Pantelis Sarafidis, Katherine R. Tuttle, Christoph Wanner, Meike Brinker, Sara Dizayee, Peter Kolkhof, Patrick Schloemer, Paula Vesterinen, Vlado Perkovic, for the FIND-CKD investigators, Julio Bittar, Cesar Javier Zaidman, Natalia Cluigt, Miguel Hominal, Paola Aguerre, Fernando Halac, Elizabeth Gelersztein, M. Arriola, Rafaël Maldonado, Mariano Chahin, David Packham, Darren J. Lee, Eugenia Pedagogos, Celine Foote, Sunil V. Badve, Carmel M. Hawley, Jenny Chen, Nicholas A. Gray, Marijn M. Speeckaert, Laura Labriola, Peter Doubel, Bart Maes, Kathleen Claes, Bernard Dubois, Irena Dimitrova, Tsvetelina Vutova, Stefan Ilchev, Svetla Stamova, Yordanka Ivanova, А М Васильева, Xiangmei Chen, Shuifu Tang, Xudong Xu, Bi‐Cheng Liu, Weiming He, Yani He, Fang Liu, Caili Wang, Lianhua Chen, Jianying Niu, Deguang Wang, Ping Luo, Yuou Xia, Gengru Jiang, Qun Luo, Fang Wang, Menghua Chen, Hongli Lin, Rui Yan, Yinan Li, Qinkai Chen, Junwu Dong, Fei Xiong, Haibo Long, Hong Cheng, Yuehong Li, Juan Du, Fanna Liu, Qingping Chen, Wanhong Lu, Chaosheng Chen, Jianqin Wang, Lei Liu, Min Yang, Gang Long, Yongjun Shi, Wenge Li, Xiangdong Yang, Aicheng Yang, Jianfei Li, Xiaoyan Meng, Martin Prázný, Lucie Hornova, Petr Bucek, Mária Majerníková, Jan Wirth, Jitka Řehořová, Mads Hornum, Jesper Nørgaard Bech, Morten Lindhardt, Ditte Hansen, Line Mortensen, Claus Bogh Juhl, Ioannis Boletis
Validity and Utility of a Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression: A Review
Dustin J. Little, Samvel B. Gasparyan, Patrick Schloemer, Niels Jongs, Meike Brinker, Martin Karpefors, Christoph Tasto, Nicole Rethemeier, Lars Frison, Richard Nkulikiyinka, Jérôme Rossert, Hiddo J.L. Heerspink
Gαi2- and Gαi3-Specific Regulation of Voltage-Dependent L-Type Calcium Channels in Cardiomyocytes
Sara Dizayee, Sonja Kaestner, Fabian Kuck, Peter Hein, Christoph Klein, Roland P. Piekorz, J. Gary Meszaros, Jan Matthes, Bernd Nürnberg, Stefan Herzig
How much of the research on Bayer (Germany) is open access?
ScholarIQopen access share
75%OPEN ACCESS